Zacks.com on MSN5d
Ascendis Pharma (ASND) Moves 17.1% Higher: Will This Strength Last?
Ascendis Pharma (ASND) saw its shares surge in the last session with trading volume being higher than average. The latest ...
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
A/S (Nasdaq: ASND) today announced that it has commenced an underwritten public offering of $300,000,000 of American ...
Morningstar3d
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
COPENHAGEN, Denmark, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the pricing of its underwritten public offering of 2,000,000 American Depositary Shares ...
Ascendis Pharma Prices Public Offering Of 2 Mln ADSs At $150.00/ADS
Ascendis Pharma A/S (ASND) said that it has priced its underwritten public offering of 2 million American Depositary Shares or 'ADSs' ...
Morningstar4d
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
COPENHAGEN, Denmark, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has commenced an underwritten public offering of $300,000,000 of American ...
Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year
Ascendis Pharma reports positive topline data from the Phase 3 ApproaCH trial of TransCon CNP in children with achondroplasia ...
Yahoo Finance3d
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
COPENHAGEN, Denmark, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the pricing of its underwritten public offering of 2,000,000 American Depositary Shares ...
FierceBiotech5d
Ascendis' dwarfism drug accelerates growth in phase 3, teeing up challenge to BioMarin
Ascendis Pharma has emerged as a potential threat to BioMarin’s Voxzogo, reporting phase 3 growth disorder data that exceeded ...